139 related articles for article (PubMed ID: 26042458)
1. Identification of ALK5 inhibitor via structure-based virtual screening and ADMET prediction.
Lin A; Cai Z; Hu G; Li Q
J Recept Signal Transduct Res; 2015; 35(6):559-64. PubMed ID: 26042458
[TBL] [Abstract][Full Text] [Related]
2. Pharmacophore modeling and virtual screening for the discovery of new transforming growth factor-beta type I receptor (ALK5) inhibitors.
Ren JX; Li LL; Zou J; Yang L; Yang JL; Yang SY
Eur J Med Chem; 2009 Nov; 44(11):4259-65. PubMed ID: 19640613
[TBL] [Abstract][Full Text] [Related]
3. Screening and identification of a novel class of TGF-β type 1 receptor kinase inhibitor.
Huynh QK; Wise SJ; Koch KA; Castonguay LA; Reid BG; Pagratis EE; Koditek D; Glascock CB; Pitts KR; Turner BA; Liu X; Hung M; Han B; Pagratis N
J Biomol Screen; 2011 Aug; 16(7):724-33. PubMed ID: 21521800
[TBL] [Abstract][Full Text] [Related]
4. Identification of novel PI3Kδ inhibitors by docking, ADMET prediction and molecular dynamics simulations.
Liu YY; Feng XY; Jia WQ; Jing Z; Xu WR; Cheng XC
Comput Biol Chem; 2019 Feb; 78():190-204. PubMed ID: 30557817
[TBL] [Abstract][Full Text] [Related]
5. Design, 3D QSAR modeling and docking of TGF-β type I inhibitors to target cancer.
Ajay Kumar TV; Athavan AAS; Loganathan C; Saravanan K; Kabilan S; Parthasarathy V
Comput Biol Chem; 2018 Oct; 76():232-244. PubMed ID: 30077902
[TBL] [Abstract][Full Text] [Related]
6. Virtual screening of small molecules databases for discovery of novel PARP-1 inhibitors: combination of in silico and in vitro studies.
Ekhteiari Salmas R; Unlu A; Bektaş M; Yurtsever M; Mestanoglu M; Durdagi S
J Biomol Struct Dyn; 2017 Jul; 35(9):1899-1915. PubMed ID: 27315035
[TBL] [Abstract][Full Text] [Related]
7. Virtual Screening of Novel Glucosamine-6-Phosphate Synthase Inhibitors.
Lather A; Sharma S; Khatkar A
Comb Chem High Throughput Screen; 2018; 21(3):182-193. PubMed ID: 29600755
[TBL] [Abstract][Full Text] [Related]
8. In silico studies on the interaction between bioactive ligands and ALK5, a biological target related to the cancer treatment.
Almeida MO; Trossini GH; Maltarollo VG; Silva Dda C; Honorio KM
J Biomol Struct Dyn; 2016 Sep; 34(9):2045-53. PubMed ID: 26524124
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis and evaluation of small molecule imidazo[2,1-b][1,3,4]thiadiazoles as inhibitors of transforming growth factor-β type-I receptor kinase (ALK5).
Patel HM; Sing B; Bhardwaj V; Palkar M; Shaikh MS; Rane R; Alwan WS; Gadad AK; Noolvi MN; Karpoormath R
Eur J Med Chem; 2015 Mar; 93():599-613. PubMed ID: 25234355
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and biological evaluation of 1,2,4-trisubstituted imidazoles as inhibitors of transforming growth factor-β type I receptor (ALK5).
Guo C; Zhang C; Li X; Li W; Xu Z; Bao L; Ding Y; Wang L; Li S
Bioorg Med Chem Lett; 2013 Nov; 23(21):5850-4. PubMed ID: 24055046
[TBL] [Abstract][Full Text] [Related]
11. Induction of heart valve lesions by small-molecule ALK5 inhibitors.
Anderton MJ; Mellor HR; Bell A; Sadler C; Pass M; Powell S; Steele SJ; Roberts RR; Heier A
Toxicol Pathol; 2011 Oct; 39(6):916-24. PubMed ID: 21859884
[TBL] [Abstract][Full Text] [Related]
12. Rapid generation of a high quality lead for transforming growth factor-beta (TGF-beta) type I receptor (ALK5).
Goldberg FW; Ward RA; Powell SJ; Debreczeni JE; Norman RA; Roberts NJ; Dishington AP; Gingell HJ; Wickson KF; Roberts AL
J Med Chem; 2009 Dec; 52(23):7901-5. PubMed ID: 19736928
[TBL] [Abstract][Full Text] [Related]
13. Exploration of the structural requirements of HIV-protease inhibitors using pharmacophore, virtual screening and molecular docking approaches for lead identification.
Islam MA; Pillay TS
J Mol Graph Model; 2015 Mar; 56():20-30. PubMed ID: 25541527
[TBL] [Abstract][Full Text] [Related]
14. Identification of novel small molecule TGF-β antagonists using structure-based drug design.
Wang H; Sessions RB; Prime SS; Shoemark DK; Allen SJ; Hong W; Narayanan S; Paterson IC
J Comput Aided Mol Des; 2013 Apr; 27(4):365-72. PubMed ID: 23625024
[TBL] [Abstract][Full Text] [Related]
15. Effective virtual screening strategy focusing on the identification of novel Bruton's tyrosine kinase inhibitors.
Xiao J; Zhang S; Luo M; Zou Y; Zhang Y; Lai Y
J Mol Graph Model; 2015 Jul; 60():142-54. PubMed ID: 26043662
[TBL] [Abstract][Full Text] [Related]
16. Novel inhibitor discovery through virtual screening against multiple protein conformations generated via ligand-directed modeling: a maternal embryonic leucine zipper kinase example.
Mahasenan KV; Li C
J Chem Inf Model; 2012 May; 52(5):1345-55. PubMed ID: 22540736
[TBL] [Abstract][Full Text] [Related]
17. Discovery of Entamoeba histolytica hexokinase 1 inhibitors through homology modeling and virtual screening.
Saucedo-Mendiola ML; Salas-Pacheco JM; Nájera H; Rojo-Domínguez A; Yépez-Mulia L; Avitia-Domínguez C; Téllez-Valencia A
J Enzyme Inhib Med Chem; 2014 Jun; 29(3):325-32. PubMed ID: 23534932
[TBL] [Abstract][Full Text] [Related]
18. Computation-based virtual screening for designing novel antimalarial drugs by targeting falcipain-III: a structure-based drug designing approach.
Kesharwani RK; Singh DV; Misra K
J Vector Borne Dis; 2013; 50(2):93-102. PubMed ID: 23995310
[TBL] [Abstract][Full Text] [Related]
19. Ligand-based virtual screening and inductive learning for identification of SIRT1 inhibitors in natural products.
Sun Y; Zhou H; Zhu H; Leung SW
Sci Rep; 2016 Jan; 6():19312. PubMed ID: 26805727
[TBL] [Abstract][Full Text] [Related]
20. High throughput virtual screening and E-pharmacophore filtering in the discovery of new BACE-1 inhibitors.
Muthusamy K; Singh KhD; Chinnasamy S; Nagamani S; Krishnasamy G; Thiyagarajan C; Premkumar P; Anusuyadevi M
Interdiscip Sci; 2013 Jun; 5(2):119-26. PubMed ID: 23740393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
